<DOC>
	<DOCNO>NCT01590199</DOCNO>
	<brief_summary>This study evaluate long-term safety tolerability pasireotide LAR combination everolimus advance metastatic NET patient , progress 12 month combination therapy pasireotide LAR everolimus .</brief_summary>
	<brief_title>Evaluate Safety Tolerability Pasireotide LAR Combination With Everolimus Advanced Metastatic NETs</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Patients eligible inclusion extension study meet additional inclusion criterion : The patient must provide sign Informed Consent Form ( ICF ) extension study prior study related procedure Completion whole treatment period 15 month ( 3 month monotherapy either pasireotide LAR everolimus follow 12 month combination pasireotide LAR/everolimus ) CSOM230F2102 study No tumor progression 12 month combination therapy pasireotide LAR everolimus ( checked via radiologically assessment ) . No intolerable toxicity combination therapy pasireotide LAR everolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>